Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 550 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nonalcoholic Fatty Liver Disease (NAFLD) Clear all
Completed Not applicable Interventional Results available

Tesamorelin Effects on Liver Fat and Histology in HIV

NCT02196831
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions
tesamorelin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Bethesda, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 14, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Vigabatrin and Insulin Sensitivity

NCT04321395
View directory record Official record
Conditions
NAFLD, Obesity
Interventions
Vigabatrin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 14, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Ketogenic Diet in Non-alcoholic Fatty Liver Disease

NCT03784716
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic, Liver Diseases
Interventions
Ketogenic Diet, Standard Weight Loss Diet
Other
Lead sponsor
Marc Goodman
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 14, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy

NCT02684591
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, HIV
Interventions
Aramchol, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 14, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Healthy Eating Through Reduction Of Excess Sugar

NCT02948647
View directory record Official record
Conditions
NAFLD
Interventions
Standard of care plus sugar-reduction education
Other
Lead sponsor
University of Southern California
Other
Eligibility
12 Years to 18 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 14, 2026, 8:41 PM EDT
Active, not recruiting No phase listed Observational

Accurate Point of Care Liver Disease Diagnostics

NCT05986916
View directory record Official record
Conditions
NAFLD, Nonalcoholic Fatty Liver
Interventions
Liverscope® exam, MR exam, FibroScan® exam (optional), Blood draw, Body measurements, Questionnaires
Diagnostic Test · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 14, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

NCT03166735
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
BI 1467335, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Coronado, California • La Jolla, California • La Mesa, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 14, 2026, 8:41 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Thermoacoustic Method for Estimating Liver Fat Fraction

NCT07321925
View directory record Official record
Conditions
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
Interventions
Thermoacoustic Enhanced Ultrasound
Device
Lead sponsor
Endra Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 14, 2026, 8:41 PM EDT
Recruiting Phase 2 Interventional

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

NCT06355310
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Empagliflozin 10 MG, Placebo Oral Tablet
Drug
Lead sponsor
Justin Ryder
Other
Eligibility
16 Years to 20 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 14, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Super HEROES: Searching How the Extract Rebaudioside Occludes Excess Steatosis

NCT03985020
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Stevia Intervention, Water Intervention
Other
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
10 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 14, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

NCT03976401
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EFX, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Huntington Park, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 14, 2026, 8:41 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

FTIH of ECC4703 in Healthy Volunteers

NCT05552274
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
ECC4703, Placebo
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 14, 2026, 8:41 PM EDT
Recruiting Not applicable Interventional

Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

NCT04054310
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Liver Multi Scan
Diagnostic Test
Lead sponsor
Perspectum
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Chandler, Arizona • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 14, 2026, 8:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects

NCT03783897
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EDP-305, Oral Contraceptive
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 14, 2026, 8:41 PM EDT
Completed No phase listed Observational

Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology As Reference

NCT04389593
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 14, 2026, 8:41 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05648214
View directory record Official record
Conditions
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
ALN-PNP, Placebo (PB)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
6
States / cities
Glendale, California • Los Angeles, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 14, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional Results available

Vitamin E for NASH Treatment in HIV Infected Individuals

NCT03669133
View directory record Official record
Conditions
NAFLD, NASH - Nonalcoholic Steatohepatitis, HIV Infections
Interventions
Vitamin E, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 14, 2026, 8:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity

NCT06335771
View directory record Official record
Conditions
Obesity, Nonalcoholic Fatty Liver, Diabetes Type 2, Healthy
Interventions
Dietary consultation weight loss intervention
Other
Lead sponsor
Bettina Mittendorfer
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 14, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional Results available

Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD

NCT02244944
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
EZ-Urso combination therapy
Drug
Lead sponsor
Gregory Graf, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 14, 2026, 8:41 PM EDT
Completed Early Phase 1 Interventional Results available

Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease

NCT00949403
View directory record Official record
Conditions
Fatty Liver
Interventions
Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 14, 2026, 8:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Liver - Healthy Brain

NCT05216796
View directory record Official record
Conditions
Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease, NAFLD, Pre-diabetes
Interventions
Diet Intervention
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
40 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 14, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

NCT02913105
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis NASH
Interventions
LMB763, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Culver City, California • Cypress, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 14, 2026, 8:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT00799578
View directory record Official record
Conditions
Fatty Liver
Interventions
Cysteamine
Drug
Lead sponsor
Joel Lavine
Other
Eligibility
10 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 14, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis

NCT03656068
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Fatty Liver, Fibrosis, Liver, Compensated Cirrhosis
Interventions
Nitazoxanide 500mg BID
Drug
Lead sponsor
Pinnacle Clinical Research, PLLC
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 14, 2026, 8:41 PM EDT